Life Science

An inactive enantiomer of nutlin-3 that may serve as a useful control for non-MDM2 related cellular activities also called enantiomer b based on the elution pattern during chiral separation of (&plusmn)-nutlin-3.

An inactive enantiomer of nutlin-3 that may serve as a useful control for non-MDM2 related cellular activities also called enantiomer b based on the elution pattern during chiral separation of (&plusmn)-nutlin-3.

A muscarinic M1 and M2 mACh receptor agonist (pKB = 5 and 3.7, respectively) that is typically used as an animal model for temporal lobe epilepsy.

A muscarinic M1 and M2 mACh receptor agonist (pKB = 5 and 3.7, respectively) that is typically used as an animal model for temporal lobe epilepsy.

A muscarinic M1 and M2 mACh receptor agonist (pKB = 5 and 3.7, respectively) that is typically used as an animal model for temporal lobe epilepsy.

A muscarinic M1 and M2 mACh receptor agonist (pKB = 5 and 3.7, respectively) that is typically used as an animal model for temporal lobe epilepsy.

An enantiomer of C75, which in racemic form is a stable FAS inhibitor that when administered leads to profound weight loss and feeding inhibition in both high-fat diet wild type obese and leptin-deficient ob/ob mice.

An enantiomer of C75, which in racemic form is a stable FAS inhibitor that when administered leads to profound weight loss and feeding inhibition in both high-fat diet wild type obese and leptin-deficient ob/ob mice.

An anti-coagulant differs from (&minus)-warfarin by being five times less potent as a vitamin K antagonist has a longer terminal elimination half-life (35-58 hours) than (&minus)-warfarin (24-33 hours).

An anti-coagulant differs from (&minus)-warfarin by being five times less potent as a vitamin K antagonist has a longer terminal elimination half-life (35-58 hours) than (&minus)-warfarin (24-33 hours).

An anti-coagulant differs from (&minus)-warfarin by being five times less potent as a vitamin K antagonist has a longer terminal elimination half-life (35-58 hours) than (&minus)-warfarin (24-33 hours).

An anti-coagulant differs from (&minus)-warfarin by being five times less potent as a vitamin K antagonist has a longer terminal elimination half-life (35-58 hours) than (&minus)-warfarin (24-33 hours).